Calprotectin in Hidradenitis Suppurativa - Conference of EHSF

31. Jan 2024 | 7 min read

Calprotectin in Hidradenitis Suppurativa - Conference of EHSF

Meet us at the 13th Conference of the European Hidradenitis Suppurativa Foundation e.V.

The conference of European Hidradenitis Suppurativa Foundation (EHSF) is an arena to discuss cutting edge data and emergent therapeutic strategies in the inflammatory disease Hidradenitis Suppurativa (HS); with a focus on the latest revelations in clinical and fundamental research and debate on diagnostic and treatments. This year the conference will be held in Lyon  starting February 7th. Gentian will be at the conference, and we are excited that a new study using the Gentian GCAL® Calprotectin Immunoassay will be presented as a poster.

 

Hidradenitis suppurativa (HS) – a chronic autoinflammatory skin condition

Hidradenitis suppurativa (HS) is a chronic autoinflammatory skin condition impacting the apocrine sweat glands. It is a relatively common disease with prevalence estimation range from 0.03% to 4% typically experiencing onset around the age of 23. The condition can lead to severe scarring and disability, imposing a substantial yet often underestimated burden on patients. Prompt diagnosis and swift initiation of treatment are crucial for avoiding tissue damage and ensuring the improved quality of life of affected individuals.

 

Finding a biomarker to help early treatment

Diagnosis is mainly relying on patient reporting and visible outbreaks. The main disease manifestations are inflammatory nodules (IN) and draining tunnels (dT). The formation of dTs is starting beneath the skin and they become apparent only when the inflammatory process has destroyed the skin to a considerable extent so as to form a suppurating skin pore.

HS is often misdiagnosed or diagnosed late due to healthcare professionals not being aware of the condition or people not consulting with a physician.1,2 Globally the diagnosis is delayed more than 7 years in average after symptoms appear. This is much longer than for other skin conditions.3 The existence of a biomarker which may be used in estimation of disease severity and predict dT formation before dTs appear in skin may become a tool for early biological treatment.

 

Can calprotectin be an aid in Hidradenitis Suppurativa?

Circulating calprotectin is an emerging biomarker in numerous inflammatory conditions like rheumatic diseases including the autoinflammatory conditions systemic juvenile idiopathic arthritis and Adult-onset Still's disease.4,5 Calprotectin is released as one of the first reactions from activated immunocytes, such as neutrophils during the inflammatory process. Consequently, calprotectin could serve as biomarker for inflammation in HS, potentially allowing a more sensitive and timely diagnosis.

 

CTA(37)

 

Study in collaboration with the ATTIKON University Hospital

Gentian is engaged in a study in collaboration with ATTIKON University Hospital to explore the value of calprotectin, using the Gentian GCAL® Calprotectin Immunoassay, in HS patients with varying disease activity and number of dTs.

Encouraging first results from this study will be presented at the 13th Conference of the European Hidradenitis Suppurativa Foundation in Lyon, 7-9th February.

 

book a meeting

 

GCAL® - Plasma and serum calprotectin 

The Gentian GCAL® Calprotectin Immunoassay is the first turbidimetric blood test for the quantitative measurement of calprotectin in plasma and serum. The assay is intended as an aid in the detection and assessment of inflammation and inflammatory response to infections. The  assay can be applied on a wide range of automated clinical chemistry analysers. Diagnostic laboratories can therefore easily apply GCAL® on their available instrumentation and thereby fill the open menu gaps.

GCAL® is CE-marked and IVDR certified*.

 

Question about circulating calprotectin and GCAL®? 

Interested in plasma and serum calprotectin? Want to know more? Please send an email to marketing@gentian.com or fill out the form below:

 

References:

  1. "People with the skin condition, hidradenitis suppurativa, need earlier diagnoses, more treatment options and wider support". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 1 February 2022
  2. Howells L et al. Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic reviewBr J Dermatol. 2021
  3. Saunte DM et al. Diagnostic delay in hidradenitis suppurativa is a global problemBr J Dermatol. 2015
  4. Ometto F et al. Calprotectin in rheumatic diseasesExp Biol Med (Maywood). 2017
  5. Manfredi M et al. Circulating Calprotectin (cCLP) in autoimmune diseases. Autoimmunity Reviews 2023

 

*This content may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country.
Gentian does not take any responsibility for accessing such information in those circumstances.

 

CE bw

 

You may also read


Calprotectin as an index of draining tunnel (dT) formation in Hidradenitis Suppurativa

Feb 13, 2024

Calprotectin as an index of draining tunnel (dT) formation in Hidradenitis Suppurativa

The complexity of the skin disease Hidradenitis Suppurativa (HS) and the role of proinflammatory signalling..

Calprotectin in Hidradenitis Suppurativa - Conference of EHSF

Jan 31, 2024

Calprotectin in Hidradenitis Suppurativa - Conference of EHSF

Meet us at the 13th Conference of the European Hidradenitis Suppurativa Foundation e.V.

Meet us in 2024 - Conferences & Exhibitions

Jan 18, 2024

Meet us in 2024 - Conferences & Exhibitions

Meet us in 2024 We will attend several trade shows, conferences and exhibitions in 2024. Here are some of the..